CONCLUSION
The prevalence of FVL mutations in our study did not appear
significantly affect abortion in primigravida. MTHFR C667T mutations
prevalence were appeared significantly have a relation to abortion.
There was no significant increase in the prevalence of combined
thrombophilia (Factor V Leiden and MTHFR C677T). The association between
combined thrombophilia and abortion did not involve prothrombin gene
G20210A mutations in the patient group. No homozygosity gene mutation
was detected in the factor V patient group. Heterozygotes were
significantly increased in the patient group compared to homozygotes for
each of the two gene mutations studied. There is an association between
some types of thrombophilia and miscarriage, but the absolute risk is
small and varies considerably among reports.
Disclosure of interests: No potential competing financial,
personal, political, intellectual, or religious interests were reported
by the authors.
Author contributions: DE designed the study and performed data
collection and analysis. MR interpreted and supervised the Lab
analysis results. NE and NH supervised the clinical
examinations and US findings. DE wrote the manuscript.All authors were involved in the revision of the manuscript.
Details of ethics approval: The clinical research study was
approved by the Institutional Review Board (IRB) of Alexandria
university hospital on 16 May 2019 with reference number 0105983.
Informed consent was obtained before participation from patients or
patient guardians in the case of incompetent patients.
Funding: This research received no specific grant from any
funding agency.